（杂志篇）：肿瘤专业领域的5-10分杂志大梳理（下）
小编注：本推文是我们公众号之前的系列推文之一，其中预见性的建议现在看来都很明智。我们不妨再回顾一下此系列推文。本篇推文中提到的5本期刊，European Journal of Cancer如推文所言，已经上涨超过了7分大关；Molecular cancer therapeutics稳定在5分多；Molecular Oncology同样也稳定在5分多；Cancer Immunology Research随着近年来免疫治疗的火爆，成功地突破了9分；而Journal of Hematology & Oncology上浮了一些，最新IF为7.33分。
在（杂志篇）：肿瘤专业领域的5-10分杂志大梳理（上）和（中）篇，我们已经分别梳理了杂志Oncotarget，Clinical Cancer Research，Cancer Research，Oncogene，International Journal of Cancer，Cancer Letters，British Journal of Cancer和Cancer。
今天我们看五个杂志：European Journal of Cancer，Molecular cancer therapeutics，Molecular Oncology，Cancer Immunology Research和Journal of Hematology & Oncology。
European Journal of Cancer是由ELSEVIER SCI LTD出版社发行的半月刊杂志，年文章量为285，European Journal of Cancer的影响因子呈稳定上升趋势，最新的影响因子是6.1分，看这趋势还会涨。
European Journal of Cancer杂志的收录范围：
The European Journal of Cancer is an international comprehensive oncology journal that publishes original research, editorial comments, review articles and news on experimental oncology, clinical oncology (medical, paediatric, radiation, surgical), and on cancer epidemiology and prevention. Letters that comment on an article previously published in the EJC are also welcomed.
最新文章举例：
The risk of myocardial infarction with aromatase inhibitors relative to tamoxifen in post-menopausal women with early stage breast cancer.Eur J Cancer. 2016 Sep 29;68:11-21.
A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours.Eur J Cancer. 2016 Sep 28;68:1-10.
Cyclin A1 expression and paclitaxel resistance in human ovarian cancer cells.Eur J Cancer. 2016 Sep 23;67:152-163.
Molecular cancer therapeutics是由AMER ASSOC CANCER RESEARCH出版社发行的月刊杂志，年文章量为277，Molecular cancer therapeutics的影响因子稳定在5-6分的区间，最新的影响因子是5.5。
Molecular cancer therapeutics杂志的收录范围：
Molecular Cancer Therapeutics will focus on basic research that has implications for cancer therapeutics in the following areas: Experimental Cancer Therapeutics, Identification of Molecular Targets, Targets for Chemoprevention, New Models, Cancer Chemistry and Drug Discovery, Molecular and Cellular Pharmacology, Molecular Classification of Tumors, and Bioinformatics and Computational Molecular Biology. The journal provides a publication forum for these emerging disciplines that is focused specifically on cancer research. Papers are stringently reviewed and only those that report results of novel, timely, and significant research and meet high standards of scientific merit will be accepted for publication.
最新文章举例：
Ibrutinib inhibits ErbB receptor tyrosine kinases and HER2-amplified breast cancer cell growth.Mol Cancer Ther. 2016 Sep 27.
ATM expression predicts Veliparib and Irinotecan sensitivity in gastric cancer by mediating P53 independent regulation of cell cycle and apoptosis.Mol Cancer Ther. 2016 Sep 16.
Development of a Novel Antibody-drug Conjugate for the Potential Treatment of Ovarian, Lung and Renal Cell Carcinoma Expressing TIM-1.Mol Cancer Ther. 2016 Sep 26.
Molecular Oncology是由ELSEVIER SCI LTD出版社发行的季刊杂志，年文章量为158，Molecular Oncology的影响因子在2012年达到最高6.7分，近几年下降，不过持续稳定在5分以上，最新的影响因子是5.3分。
Molecular Oncology杂志的收录范围：
Molecular Oncology highlights new discoveries, approaches, as well as technical developments, in basic, clinical and discovery-driven translational research. Topics include:
• Key biological processes such as cell cycle; DNA repair; apoptosis; invasion and metastasis; angiogenesis and lymphangiogenesis; cell signalling and interactive networks; immune response.
• Emerging technologies (genomics, proteomics, functional genomics, metabolomics, tissue arrays, imaging), and model systems.
•Biomarkers: diagnosis, prognosis, stratification and efficacy.
• Cancer genetics, epigenetics, and genomic instability.
• Minimal residual disease, pre-malignant lesions.
• Cancer micro-environment.
• Molecular pathology.
• Tumour immunology.
• Translational research.
• Cancer therapy (target discovery, drug design, immunotherapy, combination therapies, resistance, and individualised treatment).
• Chemotherapy, radiotherapy and surgery.
• Clinical pharmacology...
最新文章举例：
miR-634 exhibits anti-tumor activities toward hepatocellular carcinoma via Rab1A and DHX33.Mol Oncol. 2016 Sep 20.
Autophagy inhibition upregulates CD4+ tumor infiltrating lymphocyte expression via miR-155 regulation and TRAIL activation.Mol Oncol. 2016 Sep 16.
Cancer Immunology Research是由AMER ASSOC CANCER RESEARCH出版社发行的季刊杂志，年文章量为143，Cancer Immunology Research的影响因子从2013年开始飙升，2014年还是3.8，最新的影响因子已经是6.6分了，预计CIR还会继续升，不过该杂志年文章量太少，听投过该杂志的朋友说相对比较较难。
Cancer Immunology Research杂志的收录范围：
Cancer Immunology Research publishes outstanding original articles reporting major advances in cancer immunology that span the discipline from basic investigations in host-tumor interactions to developmental therapeutics in model systems, early translational studies in patients, and late-stage clinical trials.
Papers are stringently reviewed, and specific topics of interest include endogenous antitumor immunity, tumor-promoting inflammation, cancer antigens, vaccines, antibodies, cellular therapy, cytokines, immune regulation, immune suppression, immunomodulatory effects of cancer treatment, emerging technologies, and clinical investigations.
最新文章举例：
IL-2 variant circumvents ICOS+ regulatory T cell expansion and promotes NK cell activation.Cancer Immunol Res. 2016 Oct 3. pii: canimm.0195.2015.
Systemic GM-CSF recruits effector T cells into the tumor microenvironment in localized prostate cancer.Cancer Immunol Res. 2016 Sep 29.
Journal of Hematology & Oncology是由BIOMED CENTRAL LTD出版社发行的杂志，年文章量为118，Journal of Hematology & Oncology的影响因子从2008年开始持续上升，最新的影响因子已经是6.2分了，从近几年的趋势来看，该杂志影响因子保持在5分以上应该问题不大。
Journal of Hematology & Oncology杂志的收录范围：
Journal of Hematology & Oncology is an open access journal that publishes top-quality research encompassing all aspects of hematology and oncology. The journal also publishes reviews and research highlights on "hot topics" from leading experts in the field. Hematology and oncology are closely intertwined and rapidly evolving fields. More physician scientists performing laboratory-based research are rapidly bringing research in hematology and oncology from bench to bedside.
最新文章举例：
The novel thiosemicarbazone, di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone (DpC), inhibits neuroblastoma growth in vitro and in vivo via multiple mechanisms.J Hematol Oncol. 2016 Sep 27;9(1):98.
Silencing of GATA3 defines a novel stem cell-like subgroup of ETP-ALL.J Hematol Oncol. 2016 Sep 22;9(1):95.
文章解读、基金设计，扫我吧